Therefore, our results suggest LOXL2 as a contributing factor for cardiac hypertrophy, thus providing LOXL2 as a therapeutic target for cardiovascular diseases with cardiac hypertrophy and deregulated TGF-β1/Smad3 pathway, including atrial fibrillation. This evidence concerns the gene SMAD3 and cardiac hypertrophy.